{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T07:15:56Z","timestamp":1782544556124,"version":"3.54.5"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Treatment of latent tuberculosis (LTBI) is important for tuberculosis (TB) prevention, and short course rifamycin-based therapies are preferred. Once-weekly isoniazid-rifapentine by self-administered therapy (3HP-SAT) has never been compared with 4 months of daily rifampin (4R).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective cohort study of adults \u226518 years of age initiating LTBI treatment with either 3HP-SAT or 4R in a United States (US)\u2013based TB clinic between 11 April 2016 and 31 December 2018. We evaluated treatment completion through pharmacy fills and reviewed charts for reasons of noncompletion, including adverse events (AEs). The \u03c7\u200a2 test and a log-binomial multivariable model were used to compare treatment completion and AEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Five hundred sixty individuals (42%) initiated 3HP-SAT and 773 (58%) initiated 4R. Median age was 38, 55% were female, and 89% were born outside of the US. Among those aged 18\u201349 years, treatment completion with 3HP-SAT was 79% compared to 68% with 4R (adjusted risk ratio [aRR], 1.17 [95% CI, 1.17\u20131.27]; P &amp;lt; .0001). Among individuals aged \u226550 years, treatment completion with 3HP-SAT was 87% compared to 64% with 4R (aRR, 1.35 [95% CI, 1.19\u20131.52]; P &amp;lt; .0001). Compared to 4R, there was no difference in risk of AEs in the 18\u201349 age group (aRR, 0.93 [95% CI, .58\u20131.48]; P = .75). Reduced risk of AEs was noted among patients aged \u226550 years who received 3HP-SAT (aRR, 0.37 [95% CI, .16\u2013.85]; P = .02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>3HP-SAT was associated with higher LTBI treatment completion and lower rates of AEs compared to 4R in individuals aged 50 and older. Expanding 3HP-SAT as an option for patients with LTBI may enhance TB prevention strategies in the US.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1364","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T11:11:06Z","timestamp":1599649866000},"page":"e3459-e3467","source":"Crossref","is-referenced-by-count":13,"title":["Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis"],"prefix":"10.1093","volume":"73","author":[{"given":"Michelle K","family":"Haas","sequence":"first","affiliation":[{"name":"Denver Health and Hospital Authority, Denver Public Health, Denver, Colorado, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado\u2013Denver Anschutz Medical Campus, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylynn","family":"Aiona","sequence":"additional","affiliation":[{"name":"Denver Health and Hospital Authority, Denver Public Health, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine M","family":"Erlandson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado\u2013Denver Anschutz Medical Campus, Aurora, Colorado, USA"},{"name":"Division of Geriatric Medicine, Department of Medicine, University of Colorado\u2013Denver Anschutz Medical Campus, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Belknap","sequence":"additional","affiliation":[{"name":"Denver Health and Hospital Authority, Denver Public Health, Denver, Colorado, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado\u2013Denver Anschutz Medical Campus, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"2021110300152101600_CIT0001","volume-title":"Global tuberculosis report 2019","author":"World Health Organization.","year":"2019"},{"key":"2021110300152101600_CIT0002","doi-asserted-by":"crossref","first-page":"257","DOI":"10.15585\/mmwr.mm6811a2","article-title":"Tuberculosis\u2014United States, 2018","volume":"68","author":"Talwar","year":"2019","journal-title":"Morbid Mortal Wkly Rep (MMWR)"},{"key":"2021110300152101600_CIT0003","doi-asserted-by":"crossref","first-page":"e0153728","DOI":"10.1371\/journal.pone.0153728","article-title":"Recent transmission of tuberculosis\u2014United States, 2011\u20132014","volume":"11","author":"Yuen","year":"2016","journal-title":"PLoS One"},{"key":"2021110300152101600_CIT0004","doi-asserted-by":"crossref","first-page":"e27405","DOI":"10.1371\/journal.pone.0027405","article-title":"Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005\u20132009","volume":"6","author":"Ricks","year":"2011","journal-title":"PLoS One"},{"key":"2021110300152101600_CIT0005","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1473-3099(17)30248-7","article-title":"Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA","volume":"17","author":"LoBue","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021110300152101600_CIT0006","first-page":"935","article-title":"A controlled trial of community-wide isoniazid prophylaxis in Alaska","volume":"95","author":"Comstock","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"2021110300152101600_CIT0007","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies","volume":"119","author":"Comstock","year":"1979","journal-title":"Am Rev Respir Dis"},{"issue":"RR-6","key":"2021110300152101600_CIT0008","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"2021110300152101600_CIT0009","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin","volume":"130","author":"Lardizabal","year":"2006","journal-title":"Chest"},{"key":"2021110300152101600_CIT0010","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"2021110300152101600_CIT0011","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1086\/647944","article-title":"4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity","volume":"49","author":"Ziakas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2021110300152101600_CIT0012","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"2021110300152101600_CIT0013","first-page":"1374","article-title":"Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review","volume":"14","author":"Kunst","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021110300152101600_CIT0014","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials","volume":"20","author":"Campbell","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021110300152101600_CIT0015","author":"McGill University Health Center."},{"key":"2021110300152101600_CIT0016","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/cid\/cit027","article-title":"Prevention of tuberculosis in older adults in the United States: obstacles and opportunities","volume":"56","author":"Hochberg","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021110300152101600_CIT0017","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2021110300152101600_CIT0018","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine (3HP) for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021110300152101600_CIT0019","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2021110300152101600_CIT0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.amepre.2018.04.030","article-title":"Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis","volume":"55","author":"Njie","year":"2018","journal-title":"Am J Prev Med"},{"key":"2021110300152101600_CIT0021","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12879-017-2245-8","article-title":"Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine","volume":"17","author":"McClintock","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2021110300152101600_CIT0022","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"2021110300152101600_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2021110300152101600_CIT0024","article-title":"Adherence to once-weekly self-administered INH and rifapentine for latent TB: iAdhere.","author":"Belknap","year":"2015"},{"key":"2021110300152101600_CIT0025","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021110300152101600_CIT0026","doi-asserted-by":"crossref","first-page":"E928","DOI":"10.21037\/jtd.2016.08.16","article-title":"P value interpretations and considerations","volume":"8","author":"Thiese","year":"2016","journal-title":"J Thorac Dis"},{"key":"2021110300152101600_CIT0027","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.5588\/ijtld.18.0035","article-title":"Improved treatment completion with shorter treatment regimens for latent tuberculous infection","volume":"22","author":"Macaraig","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021110300152101600_CIT0028","doi-asserted-by":"crossref","first-page":"1902048","DOI":"10.1183\/13993003.02048-2019","article-title":"Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs","volume":"55","author":"Ronald","year":"2020","journal-title":"Eur Respir J"},{"key":"2021110300152101600_CIT0029","doi-asserted-by":"crossref","first-page":"ofw082","DOI":"10.1093\/ofid\/ofw082","article-title":"Predictors of latent tuberculosis infection treatment after introduction of a new regimen: a retrospective cohort study at an inner city clinic","volume":"3","author":"Yamin","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2021110300152101600_CIT0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5588\/ijtld.14.0373","article-title":"Latent tuberculous infection in the United States and Canada: who completes treatment and why?","volume":"19","author":"Hirsch-Moverman","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021110300152101600_CIT0031","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021110300152101600_CIT0032","doi-asserted-by":"crossref","first-page":"797","DOI":"10.5588\/ijtld.18.0757","article-title":"Changes in tuberculosis epidemiology, United States, 1993\u20132017","volume":"23","author":"Armstrong","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021110300152101600_CIT0033","doi-asserted-by":"crossref","first-page":"317","DOI":"10.15585\/mmwr.mm6711a2","article-title":"Tuberculosis\u2014United States, 2017","volume":"67","author":"Stewart","year":"2018","journal-title":"MMWR Morbid Mortal Wkly Rep"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1364\/33991218\/ciaa1364.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/e3459\/41058478\/ciaa1364.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/e3459\/41058478\/ciaa1364.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:16:19Z","timestamp":1635898579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/9\/e3459\/5904201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,11]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1364","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2020,9,11]]}}}